Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 537-549

  Hayden, Rachel E ^a   Pratt, Guy ^b,c   Roberts, Claudia ^b   Drayson, Mark T ^a   Bunce, Chris M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c Liverpool CR UK Centre   (United Kingdom)

Author keywords

CD40L; CLL; Lymph node; Microenvironment; Novel therapy; Protective niche

Indexed keywords

ALEMTUZUMAB; BEZAFIBRATE; CD40 LIGAND; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DASATINIB; FLUDARABINE; FOSTAMATINIB; LENALIDOMIDE; LUCATUMUMAB; LYCORINE; MEDROXYPROGESTERONE ACETATE; MILATUZUMAB; OFATUMUMAB; RITUXIMAB;

APOPTOSIS; B LYMPHOCYTE; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; CELL INTERACTION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; GENE DELETION; GENE MUTATION; HUMAN; LEUKEMIA CELL; LYMPH NODE; LYMPH NODE METASTASIS; MICROENVIRONMENT; MINIMAL RESIDUAL DISEASE; NONHUMAN; ONTOGENY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SOMATIC HYPERMUTATION; T LYMPHOCYTE;

ANTIGENS, CD40; APOPTOSIS; B-LYMPHOCYTES; CD40 LIGAND; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84859059812     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.610014     Document Type: Review

References (146)

1. O ' Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9:22-31.
2. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-764.
3. Van Gent R, Kater AP, Otto SA, et al. In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res 2008;68:10137-10144.
4. Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-861.
5. Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007;64:234-246.
6. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
7. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
9. Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular fi ltration rate. Br J Haematol 2009;145:801-805.
10. Brezinschek HP, Foster SJ, Dorner T, et al. Pairing of variable heavy and variable kappa chains in individual naive and memory B cells. J Immunol 1998;160:4762-4767.
11. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.
12. Schroeder HW Jr, Dighiero G. Th e pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15:288-294.
13. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-262.
14. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-525.
15. Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112:5122-5129.
16. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010;115:3907-3915.
17. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111:3838-3848.
18. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008;14:665-674.
19. Capasso M, Bhamrah MK, Henley T, et al. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol 2010;11:265-272.
20. Landgren O, Gridley G, Check D, et al. Acquired immune-related and infl ammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007;139:791-798.
21. Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol 2009;147:444-449.
22. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007;109:259-270.
23. Buhler A, Zenz T, Stilgenbauer S. Immunoglobulin heavy chain variable gene usage and (super)-antigen drive in chronic lymphocytic leukemia. Clin Cancer Res 2010;16:373-375.
24. Suljagic M, Longo PG, Bennardo S, et al. Th e Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010;116:4894-4905.
25. Bomben R, Dal-Bo M, Benedetti D, et al. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifi es a disease subset with peculiar clinical and biological features. Clin Cancer Res 2010;16:620-628.
26. Cyster JG. B cell follicles and antigen encounters of the third kind. Nat Immunol 2010;11:989-996.
27. Vinuesa CG, Linterman MA, Goodnow CC, et al. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010;237:72-89.
28. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
29. Dal-Bo M, Bertoni F, Forconi F, et al. Intrinsic and extrinsic factors infl uencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med 2009;7:76.
30. Coscia M, Pantaleoni F, Riganti C, et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011;25:828-837.
31. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profi ling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-1638.
32. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.
33. Albesiano E, Messmer BT, Damle RN, et al. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 2003;102:3333-3339.
34. Willenbrock K, Jungnickel B, Hansmann ML, et al. Human splenic marginal zone B cells lack expression of activation-induced cytidine deaminase. Eur J Immunol 2005;35:3002-3007.
35. Sarsotti E, Marugan I, Benet I, et al. Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia. Leukemia 2004;18:743-746.
36. Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001;14:181-192.
37. Weston-Bell N, Townsend M, Di Genova G, et al. Defi ning origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population. Leukemia 2009;23:2075-2080.
38. Seifert M, Kuppers R. Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+B cells and the dynamics of memory B cell generation. J Exp Med 2009;206:2659-2669.
39. Kitada S, Zapata JM, Andreeff M, et al. Bryostatin and CD40- ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995-1004.
40. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2663.
41. Willimott S, Baou M, Huf S, et al. Separate cell culture conditions to promote proliferation or quiescent cell survival in chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:1647-1650.
42. Lanham S, Hamblin T, Oscier D, et al. Diff erential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101: 1087-1093.
43. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007;20:399-413.
44. Dameshek W. Chronic lymphocytic leukemia-an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967; 29(Suppl.):566-584.
45. Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:153-175.
46. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental infl uences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008;264:549-562.
47. Meads MB, Hazlehurst LA, Dalton WS. Th e bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-2526.
48. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441-4450.
49. Ghia P, Granziero L, Chilosi M, et al. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 2002;12: 149-155.
50. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-2783.
51. Smit LA, Hallaert DY, Spijker R, et al. Diff erential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660-1668.
52. Herishanu Y, Perez-Galan P, Liu D, et al. Th e lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
53. Vandewoestyne ML, Pede VC, Lambein KY, et al. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles. Leukemia 2011;25:883-888.
54. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463-5472.
55. Hamilton D, Cowan RA, Sharma HL, et al. Th e behaviour of autologous indium-114m-labelled lymphocytes in patients with lymphoid cell malignancy. J Nucl Med 1988;29:485-493.
56. Wagstaff J, Gibson C, Th atcher N, et al. Th e migratory properties of indium-111 oxine labelled lymphocytes in patients with chronic lymphocytic leukemia. Br J Haematol 1981;49:283-291.
57. Jurlander J. Th e cellular biology of B-cell chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1998;27:29-52.
58. Nilsson J, Soderberg O, Nilsson K, et al. Th ioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood 2000;95:1420-1426.
59. Backman E, Bergh AC, Lagerdahl I, et al. Th ioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro. Haematologica 2007;92:1495-1504.
60. Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994;24:445-451.
61. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173-5181.
62. Deaglio S, Aydin S, Grand MM, et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 2010;16:87-91.
63. Tonino SH, Spijker R, Luijks DM, et al. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood 2008;112:840-843.
64. Hartmann TN, Grabovsky V, Wang W, et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009;69:3121-3130.
65. Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135-1144.
66. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865-873.
67. Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316-3325.
68. Scielzo C, Ten Hacken E, Bertilaccio MT, et al. How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. Leuk Lymphoma 2010;51:1371-1374.
69. Balakrishnan K, Burger JA, Quiroga MP, et al. Infl uence of bone marrow stromal microenvironment on forodesine-induced response in CLL primary cells. Blood 2010;116:1083-1091.
70. Shehata M, Schnabl S, Demirtas D, et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the anti-apoptotic eff ect of human stromal cells in chronic lymphocytic leukemia. Blood 2010;116:2513-2521.
71. Felten DL, Livnat S, Felten SY, et al. Sympathetic innervation of lymph nodes in mice. Brain Res Bull 1984;13:693-699.
72. Fink T, Weihe E. Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation? Neurosci Lett 1988;90:39-44.
73. Bellinger DL, Millar BA, Perez S, et al. Sympathetic modulation of immunity: relevance to disease. Cell Immunol 2008;252:27-56.
74. Bhowmick S, Singh A, Flavell RA, et al. Th e sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells via a TGF-betadependent mechanism. J Leukoc Biol 2009;86:1275-1283.
75. MacLennan IC. Germinal centers still hold secrets. Immunity 2005;22:656-657.
76. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22-33.
77. Natkunam Y. Th e biology of the germinal center. Hematology Am Soc Hematol Educ Program 2007:210-215.
78. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994;367:425-428.
79. Okada T, Miller MJ, Parker I, et al. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005;3:e150.
80. Grdisa M. Infl uence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leuk Res 2003;27:951-956.
81. Bromberg JS. Th e beginnings of T-B collaboration. J Immunol 2004;173:7-8.
82. D ' Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011;35:363-368.
83. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677-682.
84. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+CD25hi Foxp3+T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788-801.
85. Luqman M, Klabunde S, Lin K, et al. Th e antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711-720.
86. Burger JA, Ghia P, Rosenwald A, et al. Th e microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-3375.
87. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+T cells by producing CCL22. Eur J Immunol 2002;32:1403-1413.
88. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925-935.
89. Packham G, Stevenson F. Th e role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20:391-399.
90. Crawford DH, Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 1993;80:40-44.
91. Steele AJ, Prentice AG, Cwynarski K, et al. Th e JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2011;116:4569-4577.
92. Jacob A, Pound JD, Challa A, et al. Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40. Leuk Res 1998;22:379-382.
93. Hayden RE, Pratt G, Drayson MT, et al. Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafi brateand medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Haematologica 2010;95:1889-1896.
94. Hallaert DY, Jaspers A, van Noesel CJ, et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112:5141-5149.
95. Willimott S, Baou M, Naresh K, et al. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007;138:721-732.
96. Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403-4413.
97. Hayden RE, Pratt G, Davies NJ, et al. Treatment of primary CLL cells with bezafi brate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia 2009;23: 292-304.
98. Tromp JM, Tonino SH, Elias JA, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavychain- mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010;29:5071-5082.
99. Hallaert DY, Spijker R, Jak M, et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Diff er 2007;14:1958-1967.
100. Kater AP, Evers LM, Remmerswaal EB, et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the antiapoptotic profi le, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404-415.
101. Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004;45:2365-2372.
102. McCaig AM, Cosimo E, Leach MT, et al. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional prosurvival microenvironmental signals. Br J Haematol 2011 Feb 24. [Epub ahead of print] .
103. Coope HJ, Atkinson PG, Huhse B, et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002;21:5375-5385.
104. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556-3565.
105. Plander M, Seegers S, Ugocsai P, et al. Diff erent proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009;23:2118-2128.
106. Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:498-501.
107. Willimott S, Merriam T, Wagner SD. Apoptosis induces Bcl- XS and cleaved Bcl-XL in chronic lymphocytic leukaemia. Biochem Biophys Res Commun 2011;405:480-485.
108. Veldurthy A, Patz M, Hagist S, et al. Th e kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443-1452.
109. Amrein L, Hernandez TA, Ferrario C, et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fl udarabine in vitro. Br J Haematol 2008;143:698-706.
110. Amrein PC, Attar EC, Takvorian RW, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977-2986.
111. Zauli G, Voltan R, Bosco R, et al. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res 2011;17:762-770.
112. Krause G, Hallek M. On the assessment of dasatinib-induced autophagy in CLL. Leuk Res 2011;35:137-138.
113. Serpa M, Bendit I, Seguro F, et al. Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. Acta Haematol 2010;124:105-109.
114. Pitini VV. Th e role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes. Leuk Res 2011;35:32-33.
115. Amrein L, Soulieres D, Johnston JB, et al. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res 2011;35:99-102.
116. Harr MW, Caimi PF, McColl KS, et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Diff er 2010;17:1381-1391.
117. Song Z, Lu P, Furman RR, et al. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 2010;16:587-599.
118. Tavolaro S, Chiaretti S, Messina M, et al. Gene expression profi le of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leuk Res 2010;34:733-741.
119. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2008;30:543-588.
120. Bazargan A, Tam CS. New angles of attack in the fi ght against chronic lymphocytic leukemia: the advent of novel nonchemotherapeutic agents. Leuk Lymphoma 2010;51:1596-1611.
121. Murray JA, Khanim FL, Hayden RE, et al. Combined bezafi brate and medroxyprogesterone acetate have effi cacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol 2010;149:65-69.
122. Deininger MW, Holyoake TL. Can we aff ord to let sleeping dogs lie? Blood 2005;105:1840-1841.
123. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical effi cacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
124. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-2979.
125. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as fi rst-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
126. Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 2009;115:3830-3841.
127. Chanan-Khan A, Miller KC, Musial L, et al. Clinical effi cacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349.
128. Coiffi er B, Lepretre S, Pedersen LM, et al. Safety and effi cacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-1100.
129. Friedberg JW. CLL microenvironment: macro important. Blood 2011;117:377-378.
130. Hertlein E, Triantafi llou G, Sass EJ, et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2011;116:2554-2558.
131. Wierda WG, Castro JE, Aguillon R, et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010;24:1893-1900.
132. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619-2629.
133. Balakrishnan K, Wierda WG, Keating MJ, et al. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-1980.
134. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005;19:2195-2202.
135. Leupin N, Luthi A, Novak U, et al. P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004;45:1205-1207.
136. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2011;116:2078-2088.
137. Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-389.
138. Gorgun G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115:1797-1805.
139. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-2437.
140. Chang DH, Liu N, Klimek V, et al. Enhancement of liganddependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-621.
141. Lapalombella R, Yu B, Triantafi llou G, et al. Lenalidomide downregulates the CD20 antigen and antagonizes direct and antibodydependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180-5189.
142. Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th 17 T helper cells. Br J Haematol 2010;148:948-950.
143. Awan FT, Johnson AJ, Lapalombella R, et al. Th alidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:27-38.
144. Brown JR. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong? Leuk Lymphoma 2010; 51:1382-1385.
145. Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fl udarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010;24:1972-1975.
146. Miller KC, Musial L, Whitworth A, et al. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs 2010;14:491-499.